Stockscreener 앱 받기
15.48
4.31%
0.64
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
State Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Yahoo Finance
Arcturus Therapeutics stock hits 52-week low at $14.82 - Investing.com India
Wellington Management Group LLP Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics stock hits 52-week low at $14.82 By Investing.com - Investing.com Canada
Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Arcturus Therapeutics' SWOT analysis: mRNA vaccine stock faces pivotal year - Investing.com
Cantor Fitzgerald Reaffirms "Overweight" Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings (NASDAQ:ARCT shareholders incur further losses as stock declines 9.8% this week, taking three-year losses to 63% - Simply Wall St
Fmr LLC Sells 112,516 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 13.3%Here's Why - MarketBeat
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - The Eastern Progress Online
Arcturus Therapeutics' SWOT analysis: vaccine maker's stock faces challenges, opportunities - Investing.com Nigeria
Portolan Capital Management LLC Sells 355,763 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
ARCT (Arcturus Therapeutics Holdings) Enterprise Value : $279.5 Mil (As of Dec. 04, 2024) - GuruFocus.com
Urea Cycle Disorder Treatment Market to Grow by USD 215.4 Million (2024-2028), Driven by Rising Prevalence, with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
PDT Partners LLC Buys Shares of 75,144 Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Arcturus Therapeutics to Attend Upcoming Investor Conferences - BioSpace
Arcturus Therapeutics to Present at Major Healthcare Investor Conferences in December - StockTitan
GSA Capital Partners LLP Has $219,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Buys 712,650 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Avian Flu: FDA Authorizes Self-Replicating Vaccine Trial to Bill Gates-Backed Company, "Study Can Proceed" - presskit.it
Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data (NASDAQ:ARCT) - Seeking Alpha
Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan
Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate - BioWorld Online
Possible Signal As Arcturus Therapeutics Holdings Insiders Sell US$1.6m In Stock - Simply Wall St
Another Avian Influenza mRNA Vaccine Candidate Advances - Precision Vaccinations
Arcturus Therapeutics Holdings Inc. Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial - Marketscreener.com
What is HC Wainwright's Estimate for ARCT FY2028 Earnings? - MarketBeat
Arcturus Therapeutics’ (ARCT) Buy Rating Reiterated at HC Wainwright - Defense World
Arcturus Gets FDA Green Light for H5N1 Flu mRNA Vaccine Trial, Backed by BARDA - StockTitan
Earnings call: Arcturus Therapeutics reported a net loss of $6.9 million - Investing.com Australia
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Arcturus Therapeutics Holdings Inc. - GuruFocus.com
Arcturus Therapeutics (NASDAQ:ARCT) Receives "Buy" Rating from HC Wainwright - MarketBeat
ARK Investment Management LLC Has $48.77 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $71.40 Average Target Price from Brokerages - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call - GuruFocus.com
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... - Yahoo Finance
Arcturus Therapeutics Reports Q3 2024 Financial Results and Milestones - TipRanks
Arcturus Therapeutics Holdings Inc earnings beat by $0.31, revenue fell short of estimates - Investing.com
ARCTArcturus Therapeutics Holdings Inc. Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcturus Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
2.88%
2.65%
자본화:
|
볼륨(24시간):